SLC7A9: A Protein Associated with Neurodegenerative Diseases and Cancer

Target Name: SLC7A9

NCBI ID: G11136

Other Name(s): glycoprotein-associated amino acid transporter b0,+AT1 | SLC7A9 variant 1 | Solute carrier family 7 member 9, transcript variant 1 | b(0,+)AT1 | solute carrier family 7 (glycoprotein-associated amino acid transporter light chain, bo,+ system), member 9 | Solute carrier family 7 (cationic amino acid transporter, y+ system), member 9 | b(0,+)AT | solute carrier family 7 (cationic amino acid transporter, y+ system), member 9 | Bo,+ amino acid transporter | B(0,+)-type amino acid transporter 1 | solute carrier family 7 (amino acid transporter light chain, bo,+ system), member 9 | Solute carrier family 7 member 9 | Glycoprotein-associated amino acid transporter b0,+AT1 | CSNU3 | solute carrier family 7 member 9 | BAT1 | b(0,+)-type amino acid transporter 1 | B(0,+)AT | Solute carrier family 7 (glycoprotein-associated amino acid transporter light chain, bo,+ system), member 9, transcript variant 2 | Solute carrier family 7 (cationic amino acid transporter , y+ system) member 9 (SLC7A9) | BAT1_HUMAN | SLC7A9 variant 2

SLC7A9: A Protein Associated with Neurodegenerative Diseases and Cancer

SLC7A9 (Glycoprotein-associated amino acid transporter B0,+AT1) is a protein that is expressed in various tissues and cells in the body. It is a member of the ABC family of transport proteins, which are known for their ability to transport a wide variety of molecules across cell membranes. SLC7A9 is specifically known for its ability to transport glutamyl-containing proteins, such as the amino acid transporter B0.

SLC7A9 is a 21-kDa protein that is expressed in the brain, heart, liver, and skeletal muscle. It is primarily localized to the endoplasmic reticulum (ER), where it is involved in the transport of the amino acid glutamyl-containing protein B0. B0 is a key regulator of cell signaling and is involved in the development and maintenance of neural circuits.

SLC7A9 is a protein that has been identified as a potential drug target for several diseases. For example, SLC7A9 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, SLC7A9 has been linked to the development of certain cancers, such as breast and ovarian cancer.

SLC7A9 is also a potential biomarker for several diseases. For example, it has been shown to be elevated in the brains of individuals with Alzheimer's disease, and it has been used as a biomarker for evaluating the effectiveness of certain cancer treatments.

SLC7A9 is also known for its role in the regulation of cellular signaling pathways. For example, it has been shown to be involved in the regulation of the neurotransmitterInsulin-like growth factor (IGF-1), which is a critical regulator of cellular signaling pathways that is involved in the development and maintenance of neural circuits.

In conclusion, SLC7A9 is a protein that has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand its role in cellular signaling pathways and its potential as a therapeutic target.

Protein Name: Solute Carrier Family 7 Member 9

Functions: Associates with SLC3A1 to form a functional transporter complex that mediates the electrogenic exchange between cationic amino acids and neutral amino acids, with a stoichiometry of 1:1 (PubMed:8663357, PubMed:16825196, PubMed:32817565, PubMed:32494597). Has system b(0,+)-like activity with high affinity for extracellular cationic amino acids and L-cystine and lower affinity for intracellular neutral amino acids (PubMed:8663357, PubMed:16825196, PubMed:32494597). Substrate exchange is driven by high concentration of intracellular neutral amino acids and the intracellular reduction of L-cystine to L-cysteine (PubMed:8663357). Required for reabsorption of L-cystine and dibasic amino acids across the brush border membrane in renal proximal tubules

More Common Targets